CryoPort, Inc. $CYRX Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lessened its stake in CryoPort, Inc. (NASDAQ:CYRX) by 98.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,765 shares of the company’s stock after selling 1,129,781 shares during the period. New York State Common Retirement Fund’s holdings in CryoPort were worth $149,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC boosted its position in shares of CryoPort by 285.5% in the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock valued at $1,597,000 after purchasing an additional 194,482 shares during the period. CWM LLC increased its position in CryoPort by 56.2% during the second quarter. CWM LLC now owns 17,697 shares of the company’s stock worth $132,000 after buying an additional 6,369 shares during the period. Conestoga Capital Advisors LLC lifted its stake in CryoPort by 55.9% in the second quarter. Conestoga Capital Advisors LLC now owns 110,557 shares of the company’s stock valued at $825,000 after buying an additional 39,640 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of CryoPort by 299.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock valued at $27,000 after acquiring an additional 2,729 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of CryoPort during the second quarter worth approximately $292,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Insiders Place Their Bets

In other news, Director Ramkumar Mandalam sold 11,570 shares of CryoPort stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total transaction of $115,584.30. Following the completion of the sale, the director directly owned 80,758 shares in the company, valued at approximately $806,772.42. This trade represents a 12.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.00% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. UBS Group upped their price target on shares of CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th. Finally, Needham & Company LLC increased their target price on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.83.

CryoPort Stock Down 2.3%

Shares of CryoPort stock opened at $8.50 on Thursday. CryoPort, Inc. has a one year low of $4.58 and a one year high of $11.45. The company has a market cap of $425.60 million, a P/E ratio of 7.27 and a beta of 1.66. The company has a debt-to-equity ratio of 0.40, a quick ratio of 15.01 and a current ratio of 15.77. The firm has a fifty day moving average of $9.84 and a two-hundred day moving average of $9.35.

CryoPort Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.